SHATTUCK LABS INC
STTKNASDAQ🏆 #2774 by market capEarnings Nov 10US Equity
$5.67▼ $0.05 (−0.79%)
Latest quoteTrack STTK
Get earnings, price moves & breaking news on Telegram
24h▼ 0.8%
7d▲ 3.5%
14d▲ 4.2%
30d▼ 16.6%
ytd▲ 55.8%
1y▲ 197.6%
🏦Market Cap
$569M
Small Cap
📈Revenue Growth (YoY)
-82.5%
Declining
📊Gross Margin
-750.9%
Thin
💵FCF Margin
-4124.0%
Thin
⚖️P/S Ratio
582.6x
Expensive
Otter Score
28
Weak
Trading Snapshot
- Day Range
- $5.67 – $5.67
- 52-Week Range
- $1.72 – $8.33
- Volume (shares)
- 117
- Avg Volume (shares)
- —
- Shares Outstanding
- 100.4M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- —
- P/E Ratio
- -11.4
- P/S Ratio
- 582.6x
- EPS (TTM)
- $-0.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +104.1%
SHATTUCK LABS INC
STTKFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −82.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-195.1%▼ −1449.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$52M▼ −36.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$40M▼ −34.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
103.8M▲ +104.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$52M▼ −$2M YoY
StockOtter · stockotter.spaceAbout SHATTUCK LABS INC
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
28/100
Analyst data unavailable.
Latest News & Updates
News unavailable.